(Translated by https://www.hiragana.jp/)
Practice Research Network and Health Services Research
The Wayback Machine - https://web.archive.org/web/20110714090611/http://www.psych.org/MainMenu/Research/PracticeResearchNetworkandHealthServicesResearch.aspx

Practice Research Network and Health Services Research

The American Psychiatric Institute for Research and Education’s (APIRE) Practice Research Network (PRN) is a research initiative comprised of a nationwide network of psychiatrists who cooperate to collect data and conduct research studies on a variety of clinical and services delivery issues.  Currently comprised of over 700 psychiatrists, the PRN also conducts health services and health policy research using randomly selected samples of psychiatrists from the American Medical Association’s (AMA) physician masterfile.

The PRN was created in 1993, in recognition of the need for more practice-relevant research in the field of psychiatry.  The PRN is designed to complement traditional research methods by generating information across a broad range of patients, treatments, and treatment settings.  As a result, PRN research findings are designed to be more relevant and generalizable to day-to-day clinical decision-making. 

The PRN also plays a vital role in gathering policy relevant data.  Given the rapid changes in the organization, financing, and delivery of psychiatric care, this ongoing research laboratory provides a valuable resource for the conduct of these types of studies.

Funding from the American Psychiatric Foundation (APF), the Center for Mental Health Services, and the John D. and Catherine T. MacArthur Foundation have been instrumental in developing the PRN and its major research initiatives.  In addition, the federal Center for Substance Abuse Treatment has supported studies.   Recently, APIRE has received funding from a collaborative of pharmaceutical companies in support of the National Study of Medicaid and Medicare Psychopharmacologic Treatment Access and Continuity and the Ten State Study of Medicaid Psychopharmacologic Treatment Access and Continuity.